S

Sanofi

Global pharma company; vaccines and R&D

US Advanced Analytics Intern

Summer 2027Updated Deadline 11/5/26
$36 - $47/hr
Internship
Bachelor's, Master's
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
In PersonOnsite; work 40 hours/week, Monday to Friday, for the full internship duration. Must be able to relocate to an office location.
Data & AnalyticsData Science
No H1B Sponsorship

About the job

Requirements
  • Currently pursuing an undergraduate or master's degree in an applied quantitative field, such as mathematics, statistics, or computer science, with plans to graduate by Spring 2028 or 2029.
  • Must be permanently authorized to work in the United States and not require employment visa sponsorship, such as H-1B or green card sponsorship, at application or in the future. Students on CPT, OPT, or STEM OPT generally do not qualify unless eligible for an alternative long-term status that does not require company sponsorship.
  • Must be enrolled in an accredited college or university throughout the internship.
  • Must be able to relocate to the office location and work 40 hours per week, Monday to Friday, for the full internship duration.
  • Experience or coursework in predictive modeling and analytics.
  • Strong analytical and quantitative skills, including the ability to translate information and data into actionable insights and strategic recommendations.
  • High proficiency in Python, R, and Scala; proficiency with Snowflake; and familiarity with database systems such as SQL and NoSQL.
  • Experience with supervised learning, unsupervised learning, deep learning, reinforcement learning, federated learning, time-series forecasting, Bayesian statistics, and optimization.
  • High proficiency in Microsoft Office, including Excel, PowerPoint, and Word.
  • Ability to synthesize complex information into clear, actionable insights.
Responsibilities
  • Build effective relationships with Commercial, Commercial Brand, and Advanced Analytics stakeholders; collaborate to prioritize work and deliver on time-sensitive requests.
  • Partner with Digital Accelerator, Digital Data Science, Data Management, Market Research, Marketing, Strategy, Finance, and Business Development groups.
  • Collaborate with the extended US Advanced Analytics team.
  • Develop a model using key business insights from various markets to support commercial excellence.
  • Lead marketing- and sales-related problem-solving activities using artificial intelligence and machine learning techniques; projects may include marketing mix modeling, return-on-investment analysis, next-best action, customer segmentation, patient prediction, and driver analyses.
  • Prepare accurate, high-quality analyses using advanced analytical methods.
  • Frame key marketing and sales issues to guide model development and analysis.
  • Present model results and implications to commercial stakeholders.
  • Gather requirements, analyze data, and generate insights and reports for business use.
Desired Qualifications
  • Proactive, self-starting approach and active participation.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Yahoo Finance
Oct 30th, 2026
Sanofi shares jump 6% as it raises 2026 outlook and signals appetite for bigger deals

Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.

Yahoo Finance
Oct 30th, 2026
Sanofi lifts 2026 guidance as Q3 sales rise 14.3% to $15.6B on Dupixent strength

Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.

Yahoo Finance
Oct 30th, 2026
Sanofi raises 2026 guidance after Q3 sales rise 14.3% to $15.6B, with Dupixent up 34.8%

Sanofi raised its 2026 guidance after third-quarter sales grew 14.3% at constant exchange rates (CER) to €14,444 million. Business earnings per share (EPS) rose 19.6% at CER to €3.55. The company now expects full-year sales to grow by a low-teens percentage at CER, and business EPS by a mid-teens percentage. Dupixent sales rose 34.8% to €5.7 billion. Sales of newly launched drugs, including ALTUVIIIO, Ayvakit, and Rezurock, climbed 31.4% to €1.4 billion. Vaccines sales fell 6.6% to €3.2 billion. Selling and general expenses fell 0.9% to €2.3 billion. Research and development spending was broadly stable at €1.8 billion. Chief executive officer Belén Garijo said the company's priority is to protect earnings when Dupixent loses exclusivity.

PR Newswire
Oct 29th, 2026
Novavax earns $125M milestone as Sanofi starts Phase 3 flu-COVID vaccine trial

Novavax has earned a $125 million milestone payment after Sanofi dosed the fifth patient in a Phase 3 trial of an influenza-COVID-19 combination vaccine in Europe. The trial tests the safety and immune response of Novavax's COVID-19 vaccine, Nuvaxovid, combined with Sanofi's Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older. Novavax could receive a $75 million milestone once manufacturing technology transfer is completed, expected in mid-2027. It is also eligible for $225 million upon a US launch of a combination vaccine, plus royalties on Sanofi sales. "To date, the partnership has generated over $1 billion in revenue for Novavax," said chief executive officer John C. Jacobs.

Yahoo Finance
Oct 29th, 2026
Sanofi brings non-mRNA COVID-19 vaccine Nuvaxovid to 10 provinces and Yukon for 2026-2027

Sanofi Canada said its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, will be available in all 10 provinces and the Yukon for the 2026-2027 respiratory season. It will be offered through provincial respiratory programs and most private insurers. The vaccine is already available in British Columbia, Alberta, and Quebec. In Ontario, it should reach healthcare provider offices and public health units from the week of October 26, 2026, with pharmacies to follow. Nuvaxovid is approved for people aged 12 and older. Sanofi says pivotal phase 3 trials showed about 90% efficacy against symptomatic COVID-19. Nearly 77% of Canadian adults skipped a COVID-19 vaccine last season, according to the company. Sanofi hopes more choice will encourage uptake.